Savara Inc (NASDAQ: SVRA) announced that the first patient had been medicated in the essential IMPALA-2 scientific pilot. IMPALA-2 is a Phase 3 pilot intended to assess the effectiveness and security of molgramostim equated to placebo.  Molgramostim is a puffed groundwork of recombinant human granulocyte-macrophage colony-stimulating issue Molgramostim is a […]